Looks like you’re on the UK site. Choose another location to see content specific to your location
Sanofi names new head of Sanofi Genzyme business
Sanofi has announced the appointment of Bill Sibold as the new executive vice-president of Sanofi Genzyme, effective as of July 1st 2017.
Mr Sibold, who currently serves as head of Sanofi Genzyme's global multiple sclerosis, oncology and immunology unit, will also become a member of Sanofi's executive committee following this appointment.
He joined Sanofi in late 2011 as head of the multiple sclerosis franchise, where he oversaw the successful launches of Aubagio and Lemtrada. In his present role, he also played a key role in managing the introduction of the new drugs dupilumab and sarilumab.
As head of Sanofi Genzyme, Mr Sibold will lead the company's efforts to maintain its leadership in rare diseases, while continuing to grow in multiple sclerosis, oncology and immunology.
Olivier Brandicourt, chief executive officer of Sanofi, said: "I am confident in Bill Sibold's experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi."
He has been appointed as the successor to Dr David Meeker, who is leaving the company at the end of June after a 23-year career with Genzyme and Sanofi.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard